Oral bioavailability and brain penetration of (-)-stepholidine, a tetrahydroprotoberberine agonist at dopamine D1 and antagonist at D2 receptors, in rats

被引:28
|
作者
Sun, Yan [1 ]
Dai, Jieyu [1 ]
Hu, Zheyi [1 ]
Du, Feifei [1 ]
Niu, Wei [1 ]
Wang, Fengqing [1 ]
Liu, Fei [1 ]
Jin, Guozhang [1 ]
Li, Chuan [1 ]
机构
[1] Chinese Acad Sci, Shanghai Inst Mat Med, SIBS, Shanghai Ctr DMPK Res, Shanghai 201203, Peoples R China
基金
中国国家自然科学基金;
关键词
(-)-stepholidine; CNS drug; enterohepatic barrier; blood-brain barrier; oral bioavailability; brain penetration; metabolic profiling; prodrug; L-STEPHOLIDINE; MASS-SPECTROMETRY; METABOLISM; DRUG; QUANTIFICATION; PLASMA; D1;
D O I
10.1111/j.1476-5381.2009.00393.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and purpose: (-)-Stepholidine has high affinity for dopamine D-1 and D-2 receptors. The aims of the present study were to examine the oral bioavailability and brain penetration of (-)-stepholidine and to gain understanding of mechanisms governing its transport across the enterohepatic barrier and the blood-brain barrier. Experimental approach: The pharmacokinetics of (-)-stepholidine was studied in rats and microdialysis was used to measure delivery to the brain. These studies were supported by biological measurement of unbound (-)-stepholidine. Membrane permeability was assessed using Caco-2 cell monolayers. Metabolite profiling of (-)-stepholidine in rat bile and plasma was performed. Finally, in vitro metabolic stability and metabolite profile of (-)-stepholidine were examined to compare species similarities and differences between rats and humans. Key results: Orally administered (-)-stepholidine was rapidly absorbed from the gastrointestinal tract; two plasma concentration peaks were seen, and the second peak might result from enterohepatic circulation. Due to extensive pre-systemic metabolism, the oral bioavailability of (-)-stepholidine was poor (< 2%). However, the compound was extensively transported across the blood-brain barrier, demonstrating an AUC (area under concentration-time curve) ratio of brain : plasma of similar to 0.7. (-)-Stepholidine showed good membrane permeability that was unaffected by P-glycoprotein and multidrug resistance-associated protein 2. In vitro (-)-stepholidine was metabolized predominantly by glucuronidation and sulphation in rats and humans, but oxidation of this substrate was very low. Conclusions and implications: Although (-)-stepholidine exhibits good brain penetration, future development efforts should aim at improving its oral bioavailability by protecting against pre-systemic glucuronidation or sulphation. In this regard, prodrug approaches may be useful.
引用
收藏
页码:1302 / 1312
页数:11
相关论文
共 50 条
  • [31] D1 AND D2 DOPAMINE AGONIST SYNERGISM AND THE NUCLEUS-ACCUMBENS
    JACKSON, DM
    DREHER, K
    ROSS, SB
    TRENDS IN PHARMACOLOGICAL SCIENCES, 1987, 8 (11) : 419 - 420
  • [32] Dopamine D1 and D2 Antagonist Effects on Response Likelihood and Duration
    Choi, Won Yung
    Morvan, Cecile
    Balsam, Peter D.
    Horvitz, Jon C.
    BEHAVIORAL NEUROSCIENCE, 2009, 123 (06) : 1279 - 1287
  • [33] Preferential involvement of D1 versus D2 dopamine receptors in the effects of dopamine receptor ligands on oral ethanol self administration in rats
    Cohen, C
    Perrault, G
    Sanger, DJ
    PSYCHOPHARMACOLOGY, 1998, 140 (04) : 478 - 485
  • [34] Roles of NMDA and dopamine D1 and D2 receptors in the acquisition and expression of flavor preferences conditioned by oral glucose in rats
    Dela Cruz, J. A. D.
    Coke, T.
    Icaza-Cukali, D.
    Khalifa, N.
    Bodnar, R. J.
    NEUROBIOLOGY OF LEARNING AND MEMORY, 2014, 114 : 223 - 230
  • [35] A D1/D2 CHIMERIC DOPAMINE RECEPTOR MEDIATES A D1 RESPONSE TO A D2-SELECTIVE AGONIST
    MACKENZIE, RG
    STEFFEY, ME
    MANELLI, AM
    POLLOCK, NJ
    FRAIL, DE
    FEBS LETTERS, 1993, 323 (1-2) : 59 - 62
  • [36] CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors
    Wilcox, RE
    Tseng, T
    Brusniak, MYK
    Ginsburg, B
    Pearlman, RS
    Teeter, M
    DuRand, C
    Starr, S
    Neve, KA
    JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (22) : 4385 - 4399
  • [37] Chronic dopamine D1, dopamine D2 and combined dopamine D1 and D2 antagonist treatment in Cebus apella monkeys:: Antiamphetamine effects and extrapyramidal side effects
    Peacock, L
    Hansen, L
    Morkeberg, F
    Gerlach, J
    NEUROPSYCHOPHARMACOLOGY, 1999, 20 (01) : 35 - 43
  • [38] Chronic Dopamine D1, Dopamine D2 and Combined Dopamine D1 and D2 Antagonist Treatment in Cebus Apella Monkeys: Antiamphetamine Effects and Extrapyramidal Side Effects
    L Peacock
    L Hansen
    F Mørkeberg
    J Gerlach
    Neuropsychopharmacology, 1999, 20 : 35 - 43
  • [39] Role of D1/D2 dopamin receptors antagonist perphenazine in morphine analgesia and tolerance in rats
    Ozdemir, Ercan
    Bagcivan, Ihsan
    Gursoy, Sinan
    BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES, 2013, 13 (02) : 119 - 125
  • [40] The dopamine D1 receptor agonist and D2 receptor antagonist LEK-8829 attenuates reinstatement of cocaine-seeking in rats
    Nataša Milivojevič
    Igor Krisch
    Dušan Sket
    Marko Živin
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2004, 369 : 576 - 582